Sweden · Delayed Price · Currency is SEK NGM:MEDFIN Statistics
Total Valuation
NGM:MEDFIN has a market cap or net worth of SEK 3.90 million. The enterprise value is -1.40 million.
| Market Cap | 3.90M |
| Enterprise Value | -1.40M |
Important Dates
The next estimated earnings date is Friday, August 28, 2026.
| Earnings Date | Aug 28, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
NGM:MEDFIN has 3.42 million shares outstanding. The number of shares has increased by 24.87% in one year.
| Current Share Class | 3.34M |
| Shares Outstanding | 3.42M |
| Shares Change (YoY) | +24.87% |
| Shares Change (QoQ) | +7.93% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.83 |
| PB Ratio | 0.16 |
| P/TBV Ratio | 0.16 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.72
| Current Ratio | 1.72 |
| Quick Ratio | 1.36 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -14.57 |
Financial Efficiency
Return on equity (ROE) is -23.61% and return on invested capital (ROIC) is -13.45%.
| Return on Equity (ROE) | -23.61% |
| Return on Assets (ROA) | -11.08% |
| Return on Invested Capital (ROIC) | -13.45% |
| Return on Capital Employed (ROCE) | -23.79% |
| Weighted Average Cost of Capital (WACC) | 9.90% |
| Revenue Per Employee | 1.58M |
| Profits Per Employee | -2.02M |
| Employee Count | 3 |
| Asset Turnover | 0.14 |
| Inventory Turnover | 1.12 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -63.23% in the last 52 weeks. The beta is 1.03, so NGM:MEDFIN's price volatility has been similar to the market average.
| Beta (5Y) | 1.03 |
| 52-Week Price Change | -63.23% |
| 50-Day Moving Average | 1.73 |
| 200-Day Moving Average | 2.59 |
| Relative Strength Index (RSI) | 32.01 |
| Average Volume (20 Days) | 33,658 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, NGM:MEDFIN had revenue of SEK 4.73 million and -6.07 million in losses. Loss per share was -2.20.
| Revenue | 4.73M |
| Gross Profit | 2.15M |
| Operating Income | -5.90M |
| Pretax Income | -6.07M |
| Net Income | -6.07M |
| EBITDA | -5.37M |
| EBIT | -5.90M |
| Loss Per Share | -2.20 |
Balance Sheet
The company has 5.30 million in cash and no debt, with a net cash position of 5.30 million or 1.55 per share.
| Cash & Cash Equivalents | 5.30M |
| Total Debt | n/a |
| Net Cash | 5.30M |
| Net Cash Per Share | 1.55 |
| Equity (Book Value) | 24.80M |
| Book Value Per Share | 7.24 |
| Working Capital | 4.50M |
Cash Flow
| Operating Cash Flow | -3.29M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 534,000 |
| Net Borrowing | 3.42M |
| Free Cash Flow | -3.29M |
| FCF Per Share | -0.96 |
Margins
Gross margin is 45.47%, with operating and profit margins of -124.84% and -128.37%.
| Gross Margin | 45.47% |
| Operating Margin | -124.84% |
| Pretax Margin | -128.37% |
| Profit Margin | -128.37% |
| EBITDA Margin | -113.54% |
| EBIT Margin | -124.84% |
| FCF Margin | n/a |
Dividends & Yields
NGM:MEDFIN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -24.87% |
| Shareholder Yield | -24.87% |
| Earnings Yield | -155.44% |
| FCF Yield | -84.16% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on September 24, 2024. It was a reverse split with a ratio of 0.0025.
| Last Split Date | Sep 24, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.0025 |
Scores
NGM:MEDFIN has an Altman Z-Score of 1.05 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.05 |
| Piotroski F-Score | 2 |